- 2022.12.28
- AMED to Provide Thyas $7.2 Million (JPY 950 Million) Grant for World's First Clinical Trial of iPSC-Derived Killer T Cell Therapy
- 2022.12.20
- Thyas Enters into Joint Research Agreement and Exclusive License for Data and Patents of Clinical Manufacturing of iPSC-Derived CAR-NK Cells
- 2022.12.13
- Dr. Shin Kaneko published a new article in Nature Biomedical Engineering.
- 2022.12.07
- Thyas’ article on “Nature Milestone: T cells" - "Leading the next wave of cancer immune-cell therapies via allogeneic iPS-Ts."
- 2022.10.01
- Thyas opened Shonan office
- 2022.02.28
- Thyas Co. Ltd., a Kyoto University spin-off, Closes JPY 2.1B Series B Financing from Eight Roads Ventures/F-Prime to Develop Novel iPSC-derived Immune Cell Platform
- 2021.11.12
- Change of board structure
- 2021.11.12
- Announcement of Series A3 financing
- 2021.09.01
- Joint research on personalized cancer immunotherapy using regenerated T cells derived from iPS cells
- 2021.05.18
- Dr. Shin Kaneko published a new article in Nature Biomedical Engineering.